Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY

Alkermes plc.

2025-Q2 EPS reported $0.65 vs consensus $0.39 ▲ beat (+67.2%)

Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.
Proprietary net sales $307.2M (+14% YoY): LYBALVI $84.3M (+18%), ARISTADA $101.3M (+18%), VIVITROL $121.7M (+9%).
Adjusted EBITDA $126.5M; cash & investments $1.05B at June 30, 2025.
Company reaffirms 2025 financial expectations.
R&D spend $77.4M (+30% YoY) on alixorexton; positive Vibrance-1 phase 2 results support global phase 3.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.